TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20076843
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin therapy (INR target 1.8, range 1.5-2.0)
Study: 20076843
Drug: Standard-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-intensity warfarin therapy (INR target 2.5, range 2.0-3.0)
Study: 20076843
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin therapy
Study: 20076843
Drug: Standard-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-intensity warfarin therapy
Study: 15827573
Drug: OROS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS MPH 18 mg
Study: 15827573
Drug: OROS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS MPH 54 mg
Study: 9835257
Drug: Aspirin (n
Normalized name: ACETAMINOPHEN 250 mg / ASPIRIN 250 mg / CAFFEINE 65 mg ORAL TABLET, FILM COATED [EXCEDRIN MIGRAINE acetaminophen, aspirin (nsaid) and caffeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (n = 30)
Study: 9835257
Drug: Combined aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined aspirin and ticlopidine (nonrandomized group III, n = 31)
Study: 28128982
Drug: Armodafinil (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (a wakefulness promoting agent)
Study: 26010952
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) - 40 sessions, 5 days/week, 90 minutes, 100% oxygen at 2ATA
Study: 15982142
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy (IT)
Study: 19793724
Drug: Intranasal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal diamorphine (0.1 mg/kg)
Study: 9132194
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (0.2 mg/kg)
Study: 17302079
Drug: Intranasal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal diamorphine
Study: 3539046
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of ivermectin in a single dose
Study: 3539046
Drug: 1300 mg
Normalized name: gelatin 1300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1300 mg of diethylcarbamazine over eight days
Study: 30250339
Drug: Single-dose del
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose del Nido cardioplegia (DNC)
Study: 15863546
Drug: E+P (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: E+P (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Study: 7622762
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 puffs four times daily
Study: 3900856
Drug: Oral carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral carbamazepine
Study: 16750449
Drug: Valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 20 mg BID
Study: 17692722
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg BID
Study: 29962366
Drug: Standard community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard community treatment
Study: 2836059
Drug: i.v. melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. melphalan with concomitant oral misonidazole
Study: 29710726
Drug: ADD-discontinuation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADD-discontinuation group (N=35)
Study: 27183075
Drug: Microthreaded coronal
Normalized name: Corona Udder Butter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microthreaded coronal aspect implants (Hexplant)
Study: 27183075
Drug: Rough-surface implants
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough-surface implants (Brånemark)
Study: 27183075
Drug: Machined coronal
Normalized name: Corona Udder Butter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machined coronal aspect implants (Restore)
Study: 26092063
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg per day
Study: 26092063
Drug: Teriparatide 40
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide 40 μg per day
Study: 26092063
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 or 40 μg per day combined)
Study: 19050299
Drug: AMA1-based vaccines
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1-based vaccines
Study: 16880017
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment of MTBI
Study: 1892362
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dipyridamole, 75 mg, and acetylsalicylic acid, 330 mg, three times a day
Study: 2206782
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dipyridamole and acetylsalicylic acid
Study: 30284700
Drug: 1% FIT039
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% FIT039 patch
Study: 30284700
Drug: 3% FIT039
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% FIT039 patch
Study: 9647029
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 7 days
Study: 22726802
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 14 days
Study: 30018129
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) chemotherapy
Study: 26747438
Drug: True bifurcation
Approvals — FDA: no, EMA: no, PMDA: no
Description: True bifurcation lesions (TBL) treated with second-generation drug-eluting stents (DES)
Study: 26747438
Drug: Non-true bifurcation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-true bifurcation lesions (non-TBL) treated with second-generation drug-eluting stents (DES)
Study: 17515743
Drug: Low-intensity intramuscular
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity intramuscular electrostimulation applied to the myofascial trigger point (MTP) with an interstimulus interval of 0.5 s.
Study: 7974947
Drug: Yohimbine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (15 mg per day orally) and trazodone (50 mg per day orally)
Study: 4609555
Drug: Tetrabrom‐o‐methyl phenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabrom‐o‐methyl phenol (0.1%) after six treatments
Study: 1969436
Drug: 4% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% chlorhexidine detergent solution
Study: 18642974
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg long-acting risperidone administered intramuscularly once a month
Study: 10801241
Drug: Alprazolam with
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam with low-dose ritonavir (200 mg, four doses)
Study: 6734709
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive steroids
Study: 8653994
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of oral contraceptive steroids
Study: 6144975
Drug: Aspirin (ASA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (ASA, 100 mg daily)
Study: 27733107
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (2000 mg/d)
Study: 27733107
Drug: Mizoribine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine (12 mg/kg/d)
Study: 23039171
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 400 mg daily for 6 months
Study: 12567797
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT), 12 sessions
Study: 2486583
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine at 20 ml/hr (25 mg/hr)
Study: 2486583
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine at 10 ml/hr (25 mg/hr)
Study: 16163445
Drug: Standard axillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard axillary treatment (level I‐III axillary lymph node dissection or four node sampling)
Study: 30107241
Drug: Internet-delivered exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered exposure therapy (iExp)
Study: 22683195
Drug: Iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 320 mgI/mL (125 mL)
Study: 18754720
Drug: Placebo light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo light treatment
Study: 24438695
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (group B)
Study: 7943791
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection rate (0.5 mL/s) of 0.3% hypobaric bupivacaine
Study: 11590524
Drug: Nelfinavir-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir-containing therapy (PI treatment)
Study: 11590524
Drug: RTI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTI therapy alone
Study: 25099924
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) administered by continuous infusion and titrated to maintain BP control
Study: 20353588
Drug: Epoprostenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol infusion for 24 hours
Study: 30557377
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 24 hours
Study: 18029928
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with or without radiotherapy
Study: 25290658
Drug: Integrated Cognitive‐Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Cognitive‐Behavioral Therapy
Study: 20598832
Drug: Twelve‐Step Facilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve‐Step Facilitation Therapy
Study: 22200721
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SHF) post-treatment group
Study: 12627928
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g intravenously every 12 hours
Study: 10816399
Drug: Captopril renography
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril renography (25 mg oral dose)
Study: 6151528
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg b.d.
Study: 6151528
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg b.d.
Study: 20626264
Drug: LEDT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEDT treatment
Study: 7995828
Drug: Triiodothyronine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine (0.15 microgram/kg bolus infusion after aortic cross-clamp removal; 0.1 microgram/kg before end of CPB; 0.1 microgram/kg at 4, 9, and 14 hours after CPB)
Study: 2484510
Drug: Selenite, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenite, 200 micrograms daily
Study: 2484510
Drug: Selenate, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenate, 200 micrograms daily
Study: 2484510
Drug: L-selenomethionine, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-selenomethionine, 200 micrograms daily
Study: 2484510
Drug: High selenium
Normalized name: HIGH SELENIUM YEAST
Approvals — FDA: no, EMA: no, PMDA: no
Description: High selenium yeast, 200 micrograms daily
Study: 2484510
Drug: Inorganic selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic selenium compounds (selenite, selenate)
Study: 21995692
Drug: Simvastatin/Ezetimibe 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/Ezetimibe 10/10 mg
Study: 2465437
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg every 12 h)
Study: 28330908
Drug: Dairy intervention
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy intervention (3 servings/d equivalent to ∼900 mg Ca/d)
Study: 28330908
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual intake, achieving 1000 mg Ca/d)
Study: 17526170
Drug: Modified Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Xiaoyao Decoction (MXD) combining clomipramine 25‐50 mg/d
Study: 17526170
Drug: Clomipramine 75‐225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 75‐225 mg/d alone
Study: 11981102
Drug: Intravenous dose-adjusted
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose-adjusted UFH
Study: 7882602
Drug: cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 2.5 mg/day
Study: 3257670
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment (trimethoprim, 320 mg and sulfamethoxazole, 1600 mg)
Study: 7420563
Drug: 10-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day treatment
Study: 3257670
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment
Study: 31359499
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily plus a four-drug regimen (amoxicillin, clarithromycin, bismuth, and esomeprazole) for 14 weeks
Study: 27613357
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg oral dose prior to RAPN
Study: 22079914
Drug: Microdermabrasion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdermabrasion treatment sessions (maximum 20 sessions over the course of a year)
Study: 22079914
Drug: Microdermabrasion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdermabrasion treatment
Study: 12111597
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice daily for 7 days)
Study: 10594490
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a day placebo regimen
Study: 9122001
Drug: TRH test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH test (0.4 mg i.v.)
Study: 9122001
Drug: TRH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH and TRH with naloxone (2 mg i.v.)
Study: 22741259
Drug: Medicated thread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicated thread moxibustion of Zhuang medicine (group B)
Study: 11593638
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HBIG injection)
Study: 419164
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dosages of psychotropic drugs (neuroleptics, antidepressants, anxiolytics, psychostimulants)
Study: 19188877
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Q6H lubrication and eye closure)
Study: 19188877
Drug: Both eyes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both eyes (control and treatment)
Study: 15342805
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus radiation therapy
Study: 8606523
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg talinolol
Study: 9553680
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg talinolol
Study: 9553680
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg talinolol (twice daily)
Study: 8713783
Drug: Control (Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Heparin alone)
Study: 21559284
Drug: Intravenous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GH bolus
Study: 17304887
Drug: Ciclesonide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide, 200 microg once daily for 6 weeks
Study: 15460498
Drug: Three-day pretreatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day pretreatment with lansoprazole 30 mg twice daily
Study: 10225769
Drug: LDL apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL apheresis fortnightly plus simvastatin 40 mg/day
Study: 10225769
Drug: Colestipol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 20 g plus simvastatin 40 mg/day
Study: 3902375
Drug: Oral flupirtine
Normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flupirtine maleate (100 to 200 mg)
Study: 3902375
Drug: Oral pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentazocine (50 to 100 mg)
Study: 27435438
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (0.1 mg/kg) 10 minutes before surgery over 2 minutes
Study: 20639026
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg serlopitant
Study: 20639026
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tolterodine
Study: 16246964
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg, n=19)
Study: 19844249
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of estrogen therapy
Study: 15933313
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate treatment in trial participants (Magpie Trial)
Study: 10366994
Drug: clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel 75 mg once daily for 11 days
Study: 10366994
Drug: naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 250 mg b.i.d. for 7 days + placebo for 11 days
Study: 10366994
Drug: naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 250 mg b.i.d. for 7 days + clopidogrel 75 mg once daily for 11 days
Study: 25673206
Drug: Intra-amniotic injection
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic injection of ethacridine lactate (EL group)
Study: 20074228
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetylsalicyclic acid (ASA), acetaminophen, and caffeine
Study: 20074228
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with single substances (ASA, acetaminophen, or caffeine)
Study: 16205558
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (sham injections)
Study: 10611883
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg per day
Study: 799975
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg per day
Study: 2328752
Drug: Enzyme potentiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme potentiated desensitising vaccine (single injection in March)
Study: 42333
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chlorpheniramine and cimetidine
Study: 26717366
Drug: Sunitinib (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (25mg qd for 10 days between cycles) combined with docetaxel (40 mg) and cisplatin (50 mg) for 12 cycles (24 weeks) followed by maintenance vinorelbine (30mg TIW) until disease progression
Study: 26717366
Drug: Sunitinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib combined with chemotherapy
Study: 18949216
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg PZQ + 6 mg/kg AM
Study: 18949216
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg PZQ + AM placebo
Study: 18949216
Drug: 120 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/kg PZQ + 6 mg/kg AM
Study: 32007
Drug: Chlorothiazide twice
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorothiazide twice a day plus atenolol, metoprolol, pindolol and propranolol in single daily doses
Study: 32007
Drug: Each beta‐adrenoreceptor‐blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each beta‐adrenoreceptor‐blocking drug
Study: 17938794
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion (BI) of rFVIIa (90 microg/kg every 2 hours during surgery through day 5, then every 4 hours for days 6-10)
Study: 11780862
Drug: Repinotan (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repinotan (0.5 mg/day)
Study: 11780862
Drug: Repinotan (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repinotan (1.25 mg/day)
Study: 11780862
Drug: Repinotan (2.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repinotan (2.50 mg/day)
Study: 7797214
Drug: Metoprolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50-100 mg per day)